DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Inspra (Eplerenone) - Reviews, Ratings, Comments by Patients

 
 



Share your experience: submit a drug review

Below are Inspra (Eplerenone) reviews, ratings, comments submitted by patients and caregivers. Based on a total of 1 ratings/reviews, Inspra has an overall score of 2. The effectiveness score is 8 and the side effect score is 4. The scores are on ten point scale: 10 - best, 1 - worst. This information is not vetted and should not be cosidered as clinical evidence.
 

Inspra review by 51 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   Conn's Syndrome
Dosage & duration:   50mgs twice per day taken twice per day for the period of 4 months
Other conditions:   None
Other drugs taken:   Parriet
  
Reported Results
Benefits:   Prior to the Inspra I was on Spiractin, which I am back on now. I took the inspra to reduce possibiity of gynecomastia, which was presenting in the form of breast pain. My blood pressure normalised on both Spriractin and Inspra.
Side effects:   Severe anxiety attacks commenced approximately two months after starting, and in hind site was a slow build up, but got to the point that it interfered with normal day to day
Comments:   Spiractin originally prescribed for treatment of Conn's Syndrome, however some brease pain was experienced shortly after commencing the medication. Further consultation with treating doctor and Inspra was prescribed as alternative. Inspra commenced and side effects described above experienced so reverted to Spiractin after short time. Side effects ceased almost immediately, 48 to 72 hours after cessation of Inspra completed.
 


Share your experience: submit a drug review

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017